MASTER SERVICES AGREEMENTMaster Services Agreement • May 26th, 2021 • HCW Biologics Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 26th, 2021 Company Industry JurisdictionThis Master Services Agreement (the “Agreement”) is made effective as of 2019/03/14 (“Effective Date”), by and between EirGenix, Inc. (“EirGenix”), a corporation with its principal place of business at 101, Lane 169, Kangning St., Xizhi Dist., New Taipei City, 221, Taiwan, R.O.C. and HCW Biologics Inc., (“COMPANY”) with its principal place of business at 2929 N Commerce Parkway, Miramar, FL 33025.
HCW Biologics Inc. Miramar, Florida 33025Letter Agreement • May 26th, 2021 • HCW Biologics Inc. • Pharmaceutical preparations • Florida
Contract Type FiledMay 26th, 2021 Company Industry JurisdictionIt gives me great pleasure to offer you the position of Chief Financial Officer. I hope that you find working at HCW Biologics Inc. (the “Company”) a richly rewarding experience. This letter agreement (this “Agreement”) sets forth the terms and conditions of employment between you (“Employee”) and the Company (each, a “Party” and collectively, the “Parties”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 26th, 2021 • HCW Biologics Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 26th, 2021 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 30, 2020, by and among HCW BIOLOGICS INC., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively referred to as “Investors”.
CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([***]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 26th, 2021 • HCW Biologics Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 26th, 2021 Company Industry JurisdictionThis EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of December 24, 2020 (the “Effective Date”) by and between WUGEN, INC., a Delaware corporation, with its principal place of business at 4340 Duncan Avenue, Suite 302, St. Louis, MO 63110 (“Wugen”), and HCW BIOLOGICS INC., a Delaware corporation, with its principal place of business at 2929 North Commerce Parkway, Miramar, Florida 33025 (“HCW”). Wugen and HCW are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”